At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- APL-9796 (drug), APL-9796 (drug)
- How long the study runs
- Study runs about 29 months (dates as stated)
- About the drug or intervention
- APL-9796 — drug: 3 Cohorts are planned in Part A. · APL-9796 — drug: The decision to initiate optional Part B in WHO Group 3 PH-ILD participants will be made by the Safety Review Committee (SRC).
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 80 Years
- Who
- All
- Number of participants
- 48
- Started
- 2025-04-09
- Last checked
- 2026-05
Plain English Summary
What is this study?
- • Testing a new treatment for pulmonary arterial hypertension
- • Phase2 - 48 participants
- • The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH
Who can take part?
- • Ages 18 Years to 80 Years
- • Diagnosed with pulmonary arterial hypertension
Where?
- • London - Hammersmith/Imperial Hospital
- • Bath - Royal United Hospital Bath
- • Cambridge - Royal Papworth Hospital
- • Clydebank - Golden Jubilee Hospital
- • +2 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796. The trial will be conducted in two parts: * Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH). * Part B (optional): Up to 12 adults with WHO Group 3 - PH associated with ILD (PH-ILD).
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 80 Years
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Participant must be 18 to 80 years of age inclusive
- ✓Participants who are diagnosed with lung hypertension via right heart catheterisation (RHC), documented at any...
- ✓WHO Functional Class II or III
- ✓Participant has the CardioMEMS PA Sensor implanted.
Who cannot take part
- ✗Hospital admission related to PH within 3 months prior to Screening.
- ✗Major surgical procedure within 3 months prior to Screening, unless participant is assessed as completely recovered...
- ✗Diagnosis of PH due to human immunodeficiency virus, portal hypertension, schistosomiasis, or uncorrected congenital...
- ✗History of left-sided heart disease and/or clinically significant heart disease
- ✗History of uncontrolled systemic hypertension
See the full criteria
Where Is This Study? (6 UK sites)
Hammersmith/Imperial Hospital
London W12 0HS, United Kingdom
Royal United Hospital Bath
Bath, United Kingdom
Royal Papworth Hospital
Cambridge, United Kingdom
Golden Jubilee Hospital
Clydebank, United Kingdom
Royal Brompton Hospital
London, United Kingdom
Sheffield Teaching Hospitals
Sheffield, United Kingdom
How to Get in Touch
Sanjay Aggarwal, MD
Sponsor contactCONTACT